Open AccessCombination ACE Inhibitor and Angiotensin Receptor Blocker Therapy—Future Considerations
Author(s) -
Sica Domenic A
Publication year - 2007
Publication title -
the journal of clinical hypertension
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.909
H-Index - 67
eISSN - 1751-7176
pISSN - 1524-6175
DOI - 10.1111/j.1524-6175.2007.6359.x
Subject(s) - medicine , drug , intensive care medicine , combination therapy , angiotensin receptor , angiotensin receptor blockers , pharmacology , angiotensin converting enzyme , kidney disease , ace inhibitor , heart failure , disease , receptor , angiotensin ii , blood pressure
Angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers are regularly prescribed for the management of hypertension. Each of these drug classes has also been shown to provide survival benefits for patients with heart failure, proteinuric chronic kidney disease, and/or a high cardiac risk profile. The individual gains seen with each of these drug classes have led to speculation that their combination might offer additive if not synergistic outcome benefits. The foundation of this hypothesis, although biologically possible, has thus far not been sufficiently well proven to support the everyday use of these 2 drug classes in combination. Additional outcomes trials, which are currently proceeding to their conclusion, may provide the necessary proof to support an expanded use of these 2 drug classes in combination.